Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

APOE: The New Frontier in the Development of a Therapeutic Target towards Precision Medicine in Late-Onset Alzheimer's.

International journal of molecular sciences - 27 Jan 2021

Yang Anna, Kantor Boris, Chiba-Falek Ornit

Abstract excerpt

Alzheimer's disease (AD) has a critical unmet medical need. The consensus around the amyloid cascade hypothesis has been guiding pre-clinical and clinical research to focus mainly on targeting beta-amyloid for treating AD. Nevertheless, the vast majority of the clinical trials have repeatedly failed, prompting the urgent need to refocus on other targets and shifting the paradigm of AD drug development towards...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Molecular Targeted Therapy
Share to Age of Onset

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Alzheimer Disease

Share to Amyloid beta-Peptides

Share to Apolipoproteins E

Share to Genetic Predisposition to Disease

Share to Precision Medicine

Source

Open in PubMed Open full text

Identifiers

PMID: 33513969
DOI: 10.3390/ijms22031244
PMCID: PMC7865856

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

APOE: The New Frontier in the Development of a Therapeutic Target towards Precision Medicine in Late-Onset Alzheimer's.PMID 33513969Read ↗

Apolipoprotein E as a Therapeutic Target in Alzheimer's Disease: A Review of Basic Research and Clinical Evidence.Semantic proximity Read ↗

Protective mutations associated with APOE in Alzheimer's disease.Semantic proximity Read ↗

APOE targeting strategy in Alzheimer's disease: lessons learned from protective variants.Semantic proximity Read ↗

ApoE in Alzheimer's disease: pathophysiology and therapeutic strategies.Semantic proximity Read ↗

Apolipoprotein E in Alzheimer's disease: an update.Semantic proximity Read ↗

APOE-amyloid interaction: Therapeutic targets.Semantic proximity Read ↗

Molecular Therapeutics in Development to Treat Alzheimer’s DiseaseSemantic proximity Read ↗

Apolipoprotein E4 as a target for developing new therapeutics for Alzheimer's disease.Semantic proximity Read ↗

Unraveling APOE4's Role in Alzheimer's Disease: Pathologies and Therapeutic StrategiesSemantic proximity Read ↗

Molecular Insight into the Therapeutic Promise of Targeting APOE4 for Alzheimer's Disease.Semantic proximity Read ↗

Silencing of <i>ApoE</i> with Divalent siRNAs Drives Activation of Immune Clearance Pathways and Improves Amyloid Pathology in Mouse Models of Alzheimer’s DiseaseSemantic proximity Read ↗

Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.